[Skip to Content]
[Skip to Content Landing]
November 1995

Vancomycin Use in Ophthalmology

Author Affiliations

Chicago, Ill

Arch Ophthalmol. 1995;113(11):1353-1354. doi:10.1001/archopht.1995.01100110013001

The Centers for Disease Control and Prevention (CDC), Atlanta, Ga, recently published guidelines for controlling vancomycin hydrochloride resistance in hospitals.1 It was reported by the CDC's National Noscomial Infections Surveillance System that the percentage of vancomycin-resistant enterococcal infections increased from 0.3% to 7.9% between 1989 and 1993. Certain patient populations are more at risk for vancomycin-resistant enterococci infection or colonization, including critically ill patients, those who are immunosuppressed, patients requiring cardiothoracic or abdominal surgical procedures, patients with indwelling catheters, and those requiring prolonged hospital stays or receiving multiple antibiotics. The current treatment recommendations for severe enterococcal infections require a combination of antimicrobial agents for effective treatment.2 Many antibiotics commonly used to treat enterococcal infection, including penicillin, ampicillin, gentamicin, streptomycin, and, now, vancomycin, have already demonstrated resistance. Recent reports indicate that vancomycin-resistant enterococci can spread by patient-to-patient contact, by hand carriage of personnel, or via patient-care equipment or environmental